Royalty Report: Drugs, Disease, Therapeutic – Collection: 204323

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 19

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 19

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • HIV / AIDs
  • Diagnostic
  • Cancer
  • Biotechnology
  • Drug Discovery
  • Vaccine
  • Viral Infection
  • Autoimmune
  • Technical Know How
  • HPV

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 204323

License Grant
Korean Licensor grants an exclusive license, with the right to sublicense, under all Licensor Patent Rights and Know-How, including, without limitation, Licensors rights in Licensors Inventions, to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Program Products in the Licenses Territory in the Anti-HBV Field.
License Property
The Program Product means any pharmaceutical formulation containing a Compound for administration to humans to treat chronic Hepatitis B Virus or HBV infection.

Hepatitis B virus, or HBV, infection is a growing global health problem that can cause both acute and chronic viral infections.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.

IP relates to potential commercialization LB80380 (ANA380), a Phase II nucleotide analog for the treatment of chronic hepatitis B virus infection.

Field of Use
LB80380 (ANA380) is a nucleotide analog currently in Phase II clinical trials for the treatment of chronic HBV infection. The compound has exhibited activity in vitro against both HBV typically found in untreated patients and also HBV variants that demonstrate resistance to treatment with the nucleotide analog lamivudine, which is a currently commercialized therapy for HBV. Preclinical studies have demonstrated significant activity against HBV, low potential for drug interactions and good tolerability in a range of preclinical toxicology studies. Based on clinical trials to date, LB80380 (ANA380) appears to offer the potential for once daily dosing.

IPSCIO Record ID: 227266

License Grant
The Licensor of Korea grants an exclusive option to enter into the License Agreement, exercisable during the Option Period.

For the Option to Negotiate, Licensor grants an exclusive option to negotiate with Licensor for a license in the Licensee Territory to the Compounds for purposes of treating HIV infection in humans (the HIV Option), exercisable during the Option Period.

For the scope of the License, Licensor grants exclusive rights, with the right to sublicense, under all Licensor Patent Rights and Know-How to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Products in the Licensee Territory for purposes of treating chronic Hepatitis B Virus (HBV) infection in humans.

License Property
The compound is known as LB80380 for treating chronic Hepatitis B Virus (HBV) infection in humans, the compound designated LB80331, the compound designated LB80317, all salts, esters, prodrugs, intermediates and metabolites of LB80380, LB80331 or LB80317, any analogs or formulations as a human therapeutic for treatment of chronic HBV infection of LB80380, LB80331 or LB80317, whose manufacture, use, or sale would infringe a claim of an issued patent or pending application for a patent included in the Licensor Patent Rights; provided, however, that Licensor shall retain all rights to such analogs or formulations of LB80380, LB8033 l or LB80317 for all uses other than as a human therapeutic for treating chronic HBV infection; and all phosphorylated forms, tautomeric forms and steriochemical forms of either LB80380, LB80331 or LB80317.

Product means any pharmaceutical formulation for administration to humans to treat chronic HBV infection containing a Compound.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same; (+)-trans-( I -phosphonometh oxy-2-alkyl cycolpropyl)methyl nucleoside.

Field of Use
The field of use is for treating chronic Hepatitis B Virus (HBV) infection in humans.

IPSCIO Record ID: 6565

License Grant
The Licensor today announced the execution of a License Agreement for elvucitabine, the Company’s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection with the Licensee.

The exclusive License grants the Licensee the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan. In Phase 2 clinical trials elvucitabine has demonstrated to be safe and well tolerated and to be efficacious in both HBV and HIV infected patients. Under the terms of the Agreement, the Licensee, through a subLicense Agreement with its Chinese joint venture, T & T Pharma Co., Ltd., formed with Tianjing Institute of Pharmaceutical Research  will assume all development and regulatory responsibility and associated costs for elvucitabine.

Field of Use
The rights granted apply to the Pharmaceutical Market relating to healthcare.

IPSCIO Record ID: 362454

License Grant
Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property
The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use
The field of use includes HIV treatments.

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.

IPSCIO Record ID: 203549

License Grant
For the technology, Licensor grants the Licensee of Bermuda, an exclusive, even as to Licensor, worldwide, sub-licensable license, under the Licensors Technology, to develop, make, have made, use, sell, have sold, offer for sale and import the Licensors Compounds and Products in the Primary Fields; and to develop, make and have made the Licensors Compounds and Products in the ID Field, but without any right to sell or commercialize in the ID Field. Licensee may sublicense the rights granted.

Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.

License Property
The product is any product incorporating or comprising the Lead Compound or any other Licensors Compound in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof, the development, manufacture, sale or use of such Lead Compound or other Licensor Compound would, but for the license granted hereunder, infringe the Licensor Patent Rights or incorporates or embodies Licensor Know-How.

The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7”) oral prodrugs for chronic hepatitis C virus (“HCV”) and hepatitis B virus (“HBV”) infections, as well as other potential infectious disease indications.

ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.

Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.

Field of Use
The primary field is the HCV Field and HBV Field. Primary field shall mean either the HCV Field or the HBV Field, as applicable.

ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.

HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).

IPSCIO Record ID: 28080

License Grant
Licensee holds exclusive rights to a number of patents that have issued in the U.S. and the EU covering methods for the manufacture of our ANX-201 product candidate and of various analogs and derivatives thereof, and the use of ANX-201 in connection with the HIV.
License Property
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI resistant viruses. In preclinical studies, anti-retroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

IPSCIO Record ID: 243452

License Grant
Licensor hereby grants Licensee the exclusive right and license to practice the Licensor Patents and the Licensor Know-How in the Territory (a) to use, offer for sale, sell and have sold Licensed Products within the Field during the pre-clinical and clinical development of such Licensed Products; and (b) in preparation of, and upon commercialization of any Licensed Product, to make, have made, import, offer for sale, sell and have sold such Licensed Product within the Field during the remaining term of this Agreement.
License Property
Licensor has developed know-how and is obtaining or has obtained patent rights relating to immunostimulatory oligonucleotides containing immunostimulatory nucleic acid sequences ('ISS') which activate or stimulate an immune response.  ISS is covered by patents and patent applications filed in various countries throughout the world.

Licensed Product(s) shall mean any Compound ISS or any pharmaceutical product containing one or more Compound ISS as an active ingredient, alone or in combination with other active ingredients (including ISS) or inactive ingredients, for administration in accordance with the Forms of Administration. For the avoidance of doubt, Licensed Products may include (a) ISS together with Compound ISS and (b) any pharmaceutical product containing one or more ISS together with Compound ISS, but shall not include (x) ISS in the absence of Compound ISS or (y) any pharmaceutical product containing one or more ISS in the absence of Compound ISS.

Compound ISS shall mean any ISS which is (a) covalently bound or otherwise chemically conjugated with the Antigen and/or (b) mixed or otherwise combined with the Antigen.   For the avoidance of doubt, this specifically includes instances where the Antigen is both chemically conjugated with the ISS and also mixed or otherwise combined with the ISS.   Notwithstanding the foregoing, in the case of prophylaxis of HBV, Compound ISS does not include instances where the Antigen is mixed or otherwise combined., but not covalently bound or otherwise chemically conjugated., with the ISS.

HBV shall mean hepatitis B virus.

ISS shall mean any immunostimulatory oligonucleotide (without limitation as to structure or length) containing a nucleic acid sequence which can activate or stimulate an immune response alone or in combination with other immune responses in vitro or in vivo and wherein the nucleosides in the nucleic acid sequence can be naturally occurring or not naturally occurring and such nucleosides can be connected through any form of naturally occurring or not naturally occurring linkage.

Field of Use
Field shall mean the treatment and prophylaxis of hepatitis B virus.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 237266

License Grant
The Italian Licensor grants an exclusive, even as to Licensor, license under the Licensors Patents to make, have made, use, import, offer, sell, offer for sale and have sold Licensed Products in the Field and in the Territory.

Licensor grants a nonexclusive license to use Licensor Know-how within the Territory for any purpose consistent with the rights and obligations contained in this Agreement.

License Property
The patents and know-how are for the Licensed Compound known as Ramoplanin.

Ramoplanin is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.

Licensor is a pharmaceutical company interested in the identification and development of naturally produced compounds for the treatment of infectious diseases, and the commercialization of products based upon such compounds.

Licensor discovered and is developing a proprietary compound, Ramoplanin, and is currently conducting clinical trials in the U.S. of an oral formulation of Ramoplanin for the prevention of infectious diseases in patients carrying Vancomycin-resistant Enterococci ('VRE') and at risk of infection following chemotherapy or transplantation, with a view to registering a new pharmaceutical product for worldwide marketing under its trademark(s) and trade name(s).

Ramoplanin is in a Phase III clinical trial for the prevention of bloodstream infections caused by vancomycin-resistant enterococci, also known as VRE, and a Phase II clinical trial to assess the safety and efficacy of Ramoplanin to treat Clostridium difficile-associated diarrhea (CDAD).

Field of Use
Field means the treatment or prevention of any human disease.

If approved, Ramoplanin would be the first available antibiotic to prevent VRE bloodstream infections.

IPSCIO Record ID: 3782

License Grant
A University Research Foundation won, by settlement, an up-front payment and royalties on a drug to treat hepatitis.

The intellectual property was taken from the University and includes possible treatments for herpes, HIV, and other viruses.  The University sued the company who was gaining from the patents, asserting that a former professor had founded the Licensee company and made off with University intellectual property.  The settlement applies to worldwide sales of telbivudine, an antiviral drug used to treat Hepatitis B.

Field of Use
The rights granted apply in the use of LdT for treating Hepatitis B virus infections (HBV infections).

IPSCIO Record ID: 158370

License Grant
The Licensee received an exclusive license to all of the Korean Licensors rights to L-FMAU technology for use in the hepatitis B virus ('HBV') field as well as all other human antiviral applications. The Licensor may grant sublicenses.
License Property
L-FMAU is a pyrimidine nucleoside analogue that has been shown to be a potent inhibitor of HBV replication in vitro.
Field of Use
The Licensee shall make, have made, use, import, offer for sale, sell and have sold Licensed Products (including, but not limited to, Bulk Drug Substance) in the Territory during the term.

IPSCIO Record ID: 275821

License Grant
The Parties now desire to amend the Original Agreement with this scope added scope.

Licensor grants an exclusive license, with the right to grant sub licenses, solely under the Licensor Foreign PEG Patents solely to make, use, develop, promote, sell, offer for sale and import PEG-Infergen Products.

License Property
This amendment adds the Trademark PEG-INFERGEN.

INFERGEN (interferon alfacon-1) is a prescription medicine used to treat adults with lasting chronic (lasting a long time) hepatitis C virus (HCV) infection and certain types of liver problems.

Field of Use
The field of use based on the original agreement is Pharmaceutical preparation namely interferon in the treatment of viral, neoplastic and autoimmune diseases.

IPSCIO Record ID: 203453

License Grant
For the Co-Development license,  Licensor grants to the Licensee of Bermuda, an exclusive, except as to Licensor and its Affiliates and sublicensees, sublicensable license under the Licensor Collaboration Technology to Develop Collaboration Products for Commercialization in the Territory in the Field.

For the Commercialization license, Licensor grants an exclusive, except in the United States as to Licensor and its Affiliates and sublicensees in accordance with the terms of this Agreement, sublicensable license under the Licensor Collaboration Technology to make, have made, use, have used, sell, have sold, offer for sale, import, have imported and otherwise Commercialize Collaboration Products in the Territory in the Field.

Licensor grants an exclusive license under the Manufacturing Technology and under any Patent Rights and other intellectual property rights which may arise that are directed thereto, to develop, have developed, use, make, have made, have used, sell, have sold, offer for sale, import, have imported and otherwise Commercialize the Collaboration Products in the Territory in the Field.

License Property
Albuferon is a novel, long-acting form of interferon alpha. It is a Human Genome Sciences drug created using the Licensor's proprietary albumin fusion technology. This technology enables scientists to improve the pharmacological properties of therapeutic proteins by fusing the gene that expresses human albumin to the gene that expresses the active protein. Albuferon results from the genetic fusion of human albumin and interferon alpha 2b. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad range of cancers

Licensors product Albuferon means a polypeptide having an interferon-alpha molecule, or any variants, analogs, homologs, derivatives, modifications, mutants or fragments thereof, including species-specific modifications thereof, genetically fused to recombinant human albumin, or any variants, analogs, homologs, derivatives, modifications, mutants or fragments thereof, including species-specific modifications thereof, as a single polypeptide chain. For the sake of clarity, Albuferon shall include, but not be limited to, interferon alpha 2a and 2b, but shall not include other non-interferon-alpha molecules, such as interferon-beta or interferon-gamma.

Licensors Collaboration Technology shall mean Licensors Patent Rights and Know-How, but shall not include Manufacturing Technology.  Licensors Patent Rights and Know-how shall mean Albumin Fusion Patent Rights, Albuferon Patent Rights, and Licensors Arising Patent Rights, and, Albumin Fusion Know-How and Arising Know-How.

Field of Use
The Field shall mean all therapeutic, diagnostic and prophylactic indications in humans and animals, with specific First Indication meaning the Hepatitis C indication and general disease.

Clinical studies to date indicate that Albuferon could offer improved dosing in the treatment of chronic hepatitis C, with efficacy and safety at least comparable to the current standard of care, pegylated interferons. These results demonstrate that Albuferon is well tolerated, remains in the blood substantially longer than is reported for recombinant interferon alpha and pegylated interferon alpha, and exhibits robust antiviral activity.

IPSCIO Record ID: 26485

License Grant
The Company entered into a licensing agreement with South Africa Licensee with respect to co-development of various RNA drugs, including Ampligen® . The licensing agreement provides Licensee with an exclusive manufacturing and marketing license for certain southern hemisphere countries (including certain countries in South America, Africa and Australia as well as the United Kingdom and Ireland (the licensed territory) .
License Property
Ampligen® is a our proprietary drug to treat diseases for which adequate treatment is not available. We seek the required regulatory approvals which will allow the progressive introduction of Ampligen® for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), HIV, Hepatitis C (“HCV”) and Hepatitis B (“HBV”) in the U.S., Canada, Europe and Japan. Ampligen® is currently in phase III clinical trials in the U.S. for use in treatment of ME/CFS and is in Phase IIb clinical trials in the U.S. for the treatment of newly emerged multi-drug resistant HIV, and for the induction of cell mediated immunity in HIV patients that are under control using potentially toxic drug cocktails.

Our proprietary drug technology Ampligen® utilizes specially configured ribonucleic acid (“RNA”) and is protected by more than 350 patents worldwide with over 80 additional patent applications  pending to provide further proprietary protection in various international markets. Certain patents apply to the use of Ampligen® alone and certain patents apply to the use of Ampligen® in combination with certain other drugs. Some composition of matter patents pertain to other new medications which have a similar mechanism of action. The main U.S. ME/CFS treatment patent (#6130206) expires January 23, 2015. Our main patents covering HIV treatment (#4795744,#4820696, #5063209, and #5091374) expire on August 26, 2006, September 30, 2008, August 10, 2010, respectively; Hepatitis treatment coverage is conveyed by U.S. patent #5593973 which expires on October 15, 2014. The U.S. Ampligen® Trademark (#1,515,099) expires on December 6, 2008 and can be renewed thereafter for an additional 10 years. The U.S. FDA has granted us “orphan drug status” for our nucleic acid-derived therapeutics for ME/CFS, HIV, and renal cell carcinoma and malignant melanoma. Orphan drug status grants the Company protection against competition for a period of seven years following FDA approval, as well as certain federal tax incentives, and other regulatory benefits.

IPSCIO Record ID: 65389

License Grant
The company has entered an agreement with the University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV).  This license allows the company to develop and potentially commercialize a cure for HBV utilizing the underlying patents and technologies developed by the universities.
License Property
CRISPR sequences are expressed in bacteria and match viral DNA in a way that defends against viruses. Cas is a related immune defense mechanism that works with CRISPR to slice through a viruss DNA and eliminate it.
Field of Use
This agreement pertains to the drug industry relating to the hepatitis B virus and human papilloma virus.

IPSCIO Record ID: 7446

License Grant
The Licensor hereby grants to the Licensee, upon the terms and conditions, an exclusive, nontransferable royalty-bearing, commercial License in the territory under the Licensed Patent Rights for the purpose of making, having made, using, offering to sell, selling and importing Licensed Product(s) in the Field of Use and for granting subLicenses.
License Property
Licensed Patents
12/775,641 Use of Pyridoxamine to treat and/or prevent disears processes
12/384,902  Methods of using Pyrisocamine as a radioprotector
12/384,832  Methods of using Pyridoxamine for treating adverse health effects of chemotherapy or  effects of chemotherapy
61/508466  Methods for treating Inflammation
Field of Use
The field of use includes therapeutic applications of pyridoxamine in acute renal failure, acute renal injury, as a radiation-protectant and a chemotherapy-protectant.

IPSCIO Record ID: 245949

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license (including as to Licensor), with the right to grant sublicenses, under the Licensed Patent Rights (subject to Licensors retained right set forth), solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory. Licensor retains the nonexclusive right to make and use Compounds for internal research purposes only, provided, however, under no circumstances shall Licensor’s retained right be used for administering the Compounds to animals or humans, nor to provide Compounds to Third Parties.

Licensor hereby grants to Licensee and its Affiliates a nonexclusive license, with the right to grant sublicenses, to the Licensed Know-How solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory.

Licensor hereby grants to Licensee and its Affiliates an exclusive license (including as to Licensor), with the right to grant sublicenses, under the Aplindore Licensed Know-How (subject to Licensor’s retained right set forth below) solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory. Licensor retains the nonexclusive right to make and use Compounds for internal research purposes only, provided, however, under no circumstances shall Licensor’s retained right be used for administering the Compounds to animals or humans, nor to provide Compounds to Third Parties.

License Property
Product means a pharmaceutical product, formulation or preparation for sale and therapeutic use in humans containing one or more Compounds as a pharmaceutically active ingredient(s).

Compounds means Aplindore and pharmaceutically acceptable salts or complexes thereof, and all salts, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, hydrates, enantiomers, and racemates thereof.

Aplindore means the compound having CAS Registry Number 189681-71-8 and known as aplindore; aplindorum; aplindor; palindore; palindorum; palindor; 8H-1,4-dioxino[2,3-e]indol-8-one, 2,3,7,9-tetrahydro-2-[[(phenymethyl)amino]methyl]-,2(S)-,(2E)-2-butenedioate; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino[2,3-e]indol-8-one (E)-butenedioate; or DAB-452.

Aplindore was initially developed by the Licensor for schizophrenia and has been studied in six Phase I and Phase II clinical trials involving over 100 healthy volunteers and over 100 schizophrenic patients. The drug demonstrated excellent brain receptor occupancy and pharmacologic activity at low doses, but proved inappropriate for the treatment of this disease at the dose range tested.

Field of Use
Aplindore is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by Licensee as a treatment for Parkinson's disease and restless legs syndrome.  Restless legs syndrome (RLS) is a condition that causes an uncontrollable urge to move your legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you're sitting or lying down. Moving eases the unpleasant feeling temporarily.

Licensee expects to commence Phase II trials in Parkinson's disease and restless legs syndrome (RLS) with Aplindore during 2007, following the manufacture of clinical supplies.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.